DGAP-News: HAEMATO AG: Record sales and high level of earnings in the first nine months 2013

DGAP-News: HAEMATO AG: Record sales and high level of earnings in the first nine months 2013

ID: 318992

(firmenpresse) - DGAP-News: HAEMATO AG / Key word(s): Quarter Results/Dividend
HAEMATO AG: Record sales and high level of earnings in the first nine
months 2013

21.11.2013 / 10:13

---------------------------------------------------------------------

Record sales and high level of earnings in the first nine months 2013

In the first nine months 2013 HAEMATO AG, Berlin (ISIN: DE0006190705),
achieved IFRS Group sales of EUR 118.30 m (previous year: EUR 21.02 m) and
earnings of EUR 6.15 m (previous year: EUR 6.73 m, thereof non-recurring
profit from sales of property of EUR 6.77 m).

In the third quarter of 2013 the IFRS Group sales amounted to EUR 55.09 m
and earnings reached EUR 2.38 m. Due to the full consolidation of the
company, sales and earnings contributions of HAEMATO PHARM GmbH are
included in the (second and) third quarter 2013.

As in the previous quarter, in the third quarter 2013 the annual sales
run-rate of more than EUR 200 m was achieved. 'The further development of
the Pharma business is running successfully. On the basis of the visibility
of the profit we can confirm the established dividend policy', says Dr.
Christian Pahl, Member of the Management Board of HAEMATO AG.

About HAEMATO:

HAEMATO AG was founded in 1993 and is a stock exchange quoted
pharmaceutical company. The company is listed on the Frankfurt Stock
Exchange in the Entry Standard (Open Market) and is based in Schönefeld
Germany.

The focus of the business activities lies on the growth markets of patent
free and patent protected medicinal products. Focal points are therapies
with cancer, HIV, cardiovascular and other chronic diseases.


Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
ir(at)haemato.de


End of Corporate News

---------------------------------------------------------------------





21.11.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


241010 21.11.2013


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Reverse Aging Signs With Lifecell, And HGH Supplements Like Genf20 Plus, Sytropin And Genfx Sierra Wireless Files with European Commission and U.S. Federal Trade Commission against Nokia for Abuse of Dominant Position in GSM and 3G Essential Patents
Bereitgestellt von Benutzer: EquityStory
Datum: 21.11.2013 - 10:13 Uhr
Sprache: Deutsch
News-ID 318992
Anzahl Zeichen: 5758

contact information:

Kategorie:

Business News



Diese Pressemitteilung wurde bisher 220 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"DGAP-News: HAEMATO AG: Record sales and high level of earnings in the first nine months 2013"
steht unter der journalistisch-redaktionellen Verantwortung von

HAEMATO AG (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von HAEMATO AG



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z